{
  "docId": "019de072-7781-7512-96cc-a2b05ce755c7",
  "docSlug": "b1746432eb5f270eac90273cddb862aa",
  "documentTitle": "Bionomics | Investor Presentation Deck | 38 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 38,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Uses a vertical timeline-style list to present company highlights.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-7781-7512-96cc-a2b05ce755c7/3",
  "deckHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7",
  "deckJsonHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7.json",
  "deckAnchorHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.77,
        "x": 0.17,
        "y": 0.14
      },
      "kind": "list",
      "text": "Diversified, clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious Central Nervous System (CNS) disorders",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4da3450a-9621-4a6b-8376-3d4c4aef102d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.77,
        "x": 0.17,
        "y": 0.25
      },
      "kind": "list",
      "text": "BNC210 in Phase 2 for acute treatment in Social Anxiety Disorder (SAD) – Established clinical PoC in GAD and Fast Track designation from FDA for SAD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63189f20-b735-482b-9f25-95d10e60213f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.77,
        "x": 0.17,
        "y": 0.76
      },
      "kind": "list",
      "text": "Well-capitalized balance sheet with multiple potential near term value-driving milestones",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64d4a2c0-6d37-46d7-b968-3435e040692a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.77,
        "x": 0.17,
        "y": 0.35
      },
      "kind": "list",
      "text": "BNC210 in ongoing Phase 2b ATTUNE trial with Fast Track designation from FDA for PTSD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8482f2fe-208a-45f6-a863-d11e30017a38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.77,
        "x": 0.17,
        "y": 0.66
      },
      "kind": "list",
      "text": "Pipeline of partnering candidates targeting potassium (Kv) and sodium (Nav) ion channels",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86ec1983-87ec-4871-8bc0-ae4983f75128",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.77,
        "x": 0.17,
        "y": 0.56
      },
      "kind": "list",
      "text": "Strategic partnership with Merck & Co. for cognitive impairment in Alzheimer’s disease and other CNS conditions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4c22303-cde1-4e65-bcf0-7bb978373868",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.77,
        "x": 0.17,
        "y": 0.45
      },
      "kind": "list",
      "text": "Large underserved markets with over 22 million patients in the United States alone suffering from SAD and PTSD and no new FDA approved therapies in nearly two decades",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df34aa47-6e3a-4244-a024-00422f11cab1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.14,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "PoC = Proof of Concept; GAD = Generalized Anxiety Disorder; PTSD = Post-Traumatic Stress Disorder; 1. Wise et al 2020, Biological Psychiatry; Perkins et al 2021, Molecular Psychiatry",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9454126a-3498-4979-96e6-9496e93d7a9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.08,
        "y": 0.04
      },
      "kind": "title",
      "text": "Emerging Leader in Neuropsychiatry",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1365ce58-129d-41cb-a1cc-dca028f612c8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "a93c3b4a-8aa1-46cb-8ee6-bcf26794f971",
      "evidence": "This slide is titled 'Emerging Leader in Neuropsychiatry' and contains a list of bullet points summarizing the company's overview.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "81e8de65-64c0-4f8c-8f98-ef1433726444",
      "evidence": "Vertical list of company highlights",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 3,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "534850f6-e55a-4574-9629-3b850bee51af",
      "evidence": "The executive summary on page 3 presents an overview of Bionomics as an emerging leader in neuropsychiatry.",
      "position": 0,
      "objective": "Why Bionomics?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}